Floatz logo

sys6043

Advanced/Metastatic Solid Tumors

CSPC Megalith Biopharmaceutical Co.,Ltd.Phase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

22 Active assets in the Advanced/Metastatic Solid Tumors cohort.

Asset / SponsorPhaseRating
ADG 106
Adagene Inc
Phase 1/2B
Pembrolizumab
Merck Sharp & Dohme LLC
Phase 1/2CCC
Muzastotug
Adagene Inc
Phase 1/2CCC
immunoglobulin G1- kappa, anti-[Homo sapiens CTLA4 (cytotoxic T-lymphocyte associated protein 4, CTLA-4, CD152)], monoclonal antibody (Firastotug)
Adagene Inc
Phase 1CCC
mhb088c for
Qilu Pharmaceutical Co., Ltd.
Phase 1/2CC

View all 33 →

Same molecule, other indications

sys6043 is also rated in:

cancerDormant
CC
Indicative ·
45 / 100
View asset →
metastatic malignant neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
prostate disorderDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →